Tesamorelin vs AOD-9604

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Full details →

AOD-9604

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.

Full details →

Side-by-Side Comparison

AspectTesamorelinAOD-9604
MechanismStimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue.Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors.
Typical DosageFDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules.Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg.
AdministrationSubcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening.Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects.
Side EffectsCommon side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose.Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH.
Best For

What They Have in Common

Both Tesamorelin and AOD-9604 are commonly used for:

Key Differences

Ready to Learn More?